{"article_title": "Up 23%: Time to Buy Exelixis? -- The Motley Fool", "article_keywords": ["fool", "zelboraf", "buy", "23", "motley", "trials", "exelixis", "drug", "cobimetinib", "williamson", "video", "survivalof", "think", "today"], "article_url": "http://www.fool.com/investing/general/2014/07/14/up-23-time-to-buy-exelixis.aspx", "article_text": "Exelixis (NASDAQ:EXEL) had a great day in the market today, up 23% on the news that its drug cobimetinib in combination with Roche's (NASDAQOTH:RHHBY) drug Zelboraf succeeded in a phase 3 trial's primary endpoint of extending progression-free survival.\n\nOf course, cobimetinib isn't all investors should think about regarding Exelixis: Cometriq will also be important. In the video below, health care analysts Michael Douglass and David Williamson give their take on Exelixis.", "article_metadata": {"publish_time": "17:30", "description": "A great day today, but is it time to buy?", "ResponsiveALP": "1Ses_2things-v-single_single-control_50", "author": "Michael Douglass and Dave Williamson", "promo": "A great day today, but is it time to buy?", "twitter": {"title": "Up 23%: Time to Buy Exelixis? --  The Motley Fool", "description": "A great day today, but is it time to buy?", "site": "@themotleyfool"}, "msvalidate.01": "8D40D58712924715BAA79D135A6C8DDA", "og": {"site_name": "The Motley Fool", "description": "A great day today, but is it time to buy?", "title": "Up 23%: Time to Buy Exelixis? --  The Motley Fool", "url": "http://www.fool.com/investing/general/2014/07/14/up-23-time-to-buy-exelixis.aspx", "image": "https://g.foolcdn.com/image/?url=http%3A%2F%2Fg.foolcdn.com%2Fassets%2Fimages%2Ffool%2Ftmf-logo.png&h=630&w=1200&op=resize", "type": "article"}, "headline": "Up 23%: Time to Buy Exelixis?", "fb": {"admins": 50808187550, "page_id": 7240312795, "app_id": 50808187550}, "bureau": "usmf-health-care", "STORY_UID": "69089910-0b99-11e4-9a2b-0050569d4be0", "pitch": 823, "date": "2014-07-14T21:30:00Z", "gsa_date": "2014 07 14", "tickers": "EXEL,RHHBY", "viewport": "width=device-width, initial-scale=1.0, maximum-scale=1.0"}, "_id": "\"57477af36914bd0286fca3b8\"", "article_summary": "In the video below, health care analysts Michael Douglass and David Williamson give their take on Exelixis.\nOf course, cobimetinib isn't all investors should think about regarding Exelixis: Cometriq will also be important.\nExelixis (NASDAQ:EXEL) had a great day in the market today, up 23% on the news that its drug cobimetinib in combination with Roche's (NASDAQOTH:RHHBY) drug Zelboraf succeeded in a phase 3 trial's primary endpoint of extending progression-free survival."}